menu
    • menu
    [{"orgOrder":0,"company":"Endeavor Biomedicines","sponsor":"Omega Funds","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"","productType":"Small molecule","year":"2021","type":"Series A Financing","leadProduct":"Taladegib","moa":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Endeavor Biomedicines","amount2":0.059999999999999998,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0.059999999999999998,"dosageForm":"","sponsorNew":"Endeavor Biomedicines \/ Omega Funds","highestDevelopmentStatusID":"8","companyTruncated":"Endeavor Biomedicines \/ Omega Funds"},{"orgOrder":0,"company":"Endeavor Biomedicines","sponsor":"Ally Bridge Group","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"","productType":"Small molecule","year":"2022","type":"Series B Financing","leadProduct":"Taladegib","moa":"PTCH1 receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Endeavor Biomedicines","amount2":0.10000000000000001,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0.10000000000000001,"dosageForm":"Tablet","sponsorNew":"Endeavor Biomedicines \/ Ally Bridge Group","highestDevelopmentStatusID":"8","companyTruncated":"Endeavor Biomedicines \/ Ally Bridge Group"},{"orgOrder":0,"company":"Endeavor Biomedicines","sponsor":"xCures","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Partnership","leadProduct":"Taladegib","moa":"Hedgehog signaling pathway","graph1":"Oncology","graph2":"Phase II","graph3":"Endeavor Biomedicines","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Endeavor Biomedicines \/ xCures","highestDevelopmentStatusID":"8","companyTruncated":"Endeavor Biomedicines \/ xCures"},{"orgOrder":0,"company":"Endeavor Biomedicines","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Taladegib","moa":"Hedgehog pathway","graph1":"Oncology","graph2":"Phase II","graph3":"Endeavor Biomedicines","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Endeavor Biomedicines \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Endeavor Biomedicines \/ Not Applicable"},{"orgOrder":0,"company":"Endeavor Biomedicines","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Taladegib","moa":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Endeavor Biomedicines","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Endeavor Biomedicines \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Endeavor Biomedicines \/ Not Applicable"},{"orgOrder":0,"company":"Endeavor Biomedicines","sponsor":"Hummingbird Bioscience","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2023","type":"Licensing Agreement","leadProduct":"HMBD-501","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Endeavor Biomedicines","amount2":0.42999999999999999,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0.42999999999999999,"dosageForm":"","sponsorNew":"Endeavor Biomedicines \/ Endeavor BioMedicines","highestDevelopmentStatusID":"4","companyTruncated":"Endeavor Biomedicines \/ Endeavor BioMedicines"},{"orgOrder":0,"company":"Endeavor Biomedicines","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Taladegib","moa":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Endeavor Biomedicines","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Endeavor Biomedicines \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Endeavor Biomedicines \/ Not Applicable"},{"orgOrder":0,"company":"Endeavor Biomedicines","sponsor":"AyurMaya","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"","productType":"Small molecule","year":"2024","type":"Series C Financing","leadProduct":"Taladegib","moa":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Endeavor Biomedicines","amount2":0.13,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0.13,"dosageForm":"Tablet","sponsorNew":"Endeavor Biomedicines \/ AyurMaya","highestDevelopmentStatusID":"8","companyTruncated":"Endeavor Biomedicines \/ AyurMaya"},{"orgOrder":0,"company":"Endeavor Biomedicines","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Taladegib","moa":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Endeavor Biomedicines","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Endeavor Biomedicines \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Endeavor Biomedicines \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals by Endeavor Biomedicines

    Menu

    Endeavor Biomedicines

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Endeavor Biomedicines

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed

                            Endeavor Biomedicines

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Taladegib

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            ENV-101 Phase 2a Shows Lung Function, Fibrosis Reversal in IPF

                            Details : ENV-101 (taladegib) is an oral small molecule inhibitor of the Hedgehog (Hh) signaling pathway. It is being evaluated in phase 2 clinical studies for the treatment of idiopathic pulmonary fibrosis.

                            Brand Name : ENV-101

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            May 19, 2024

                            Lead Product(s) : Taladegib

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Endeavor Biomedicines

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed

                            Endeavor Biomedicines

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Taladegib

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Study Phase : Phase II

                            Sponsor : AyurMaya

                            Deal Size : $132.5 million

                            Deal Type : Series C Financing

                            DEALS_DEV arrow-down

                            Endeavor Raises $132.5 Million in Oversubscribed Series C for Medicines Pipeline

                            Details : Endeavor will use the financing proceeds to advance the clinical development of ENV-101, its lead candidate for the treatment of idiopathic pulmonary fibrosis.

                            Brand Name : ENV-101

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            April 24, 2024

                            Lead Product(s) : Taladegib

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Highest Development Status : Phase II

                            Sponsor : AyurMaya

                            Deal Size : $132.5 million

                            Deal Type : Series C Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Endeavor Biomedicines

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed

                            Endeavor Biomedicines

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Taladegib

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Endeavor Completes Phase 2a Of ENV-101 In Patients With Idiopathic Pulmonary Fibrosis

                            Details : ENV-101 (taladegib) is an oral small molecule inhibitor of the Hedgehog (Hh) signaling pathway. It is being evaluated in phase 2 clinical studies for the treatment of idiopathic pulmonary fibrosis.

                            Brand Name : ENV-101

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            January 24, 2024

                            Lead Product(s) : Taladegib

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Endeavor Biomedicines

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed

                            Endeavor Biomedicines

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : HMBD-501

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Recipient : Hummingbird Bioscience

                            Deal Size : $430.0 million

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Endeavor BioMedicines Enters License Agreement with Hummingbird Bioscience for Worldwide Rights to HMBD-501, a...

                            Details : Under the agreement, Endeavor has acquired exclusive worldwide rights to Hummingbird Bio’s HMBD-501, a next-generation HER3-targeted antibody-drug conjugate (ADC).

                            Brand Name : HMBD-501

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            October 19, 2023

                            Lead Product(s) : HMBD-501

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Recipient : Hummingbird Bioscience

                            Deal Size : $430.0 million

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Endeavor Biomedicines

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed

                            Endeavor Biomedicines

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Taladegib

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Endeavor BioMedicines Completes Enrollment in Phase 2a Clinical Trial of ENV-101 (Taladegib) for the Treatment...

                            Details : ENV-101 (taladegib) is a small-molecule inhibitor of the Hedgehog (Hh) signaling pathway, which plays a critical role in idiopathic pulmonary fibrosis disease pathology.

                            Brand Name : ENV-101

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            September 06, 2023

                            Lead Product(s) : Taladegib

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Endeavor Biomedicines

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed

                            Endeavor Biomedicines

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Taladegib

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : xCures

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            Endeavor BioMedicines Partners with xCures to Identify Patients with PTCH1 mutations for Phase 2 Trial of ENV-...

                            Details : The partnership helps identify patients whose cancers harbor the PTCH1 mutation and may be eligible for Endeavor’s clinical trial for ENV-101 (taladegib). The xCures platform also enables patients to find more suitable treatment options if they are ine...

                            Brand Name : ENV-101

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            May 31, 2022

                            Lead Product(s) : Taladegib

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : xCures

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Endeavor Biomedicines

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed

                            Endeavor Biomedicines

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Taladegib

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Endeavor Doses First Patient in Phase 2 Oncology Study Evaluating the Safety and Efficacy of ENV-101 (Taladegi...

                            Details : ENV-101 (taladegib), an orally available small molecule inhibitor of the Hedgehog signaling pathway, has already demonstrated preliminary clinical efficacy and safety in nearly 200 subjects enrolled across six completed studies.

                            Brand Name : ENV-101

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            May 25, 2022

                            Lead Product(s) : Taladegib

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Endeavor Biomedicines

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed

                            Endeavor Biomedicines

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Taladegib

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Study Phase : Phase II

                            Sponsor : Ally Bridge Group

                            Deal Size : $101.0 million

                            Deal Type : Series B Financing

                            DEALS_DEV arrow-down

                            Endeavor BioMedicines Closes $101M Series B Financing to Advance Clinical-Stage Precision Medicine Pipeline

                            Details : Proceeds will support the Endeavor’s pipeline, including ENV-101 (taladegib), a small molecule inhibitor of PTCH1 receptor, for the treatment of cancer and idiopathic pulmonary fibrosis and ENV-201, a small molecule inhibitor of ULK1/2 for the treatmen...

                            Brand Name : ENV-101

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            February 07, 2022

                            Lead Product(s) : Taladegib

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Highest Development Status : Phase II

                            Sponsor : Ally Bridge Group

                            Deal Size : $101.0 million

                            Deal Type : Series B Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Endeavor Biomedicines

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed

                            Endeavor Biomedicines

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Taladegib

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Study Phase : Phase I

                            Sponsor : Omega Funds

                            Deal Size : $62.0 million

                            Deal Type : Series A Financing

                            DEALS_DEV arrow-down

                            Endeavor BioMedicines Launches with $62 Million Series A Financing and Mission to Reverse the Course of Devast...

                            Details : Proceeds from the financing will be used to advance taladegib, an inhibitor of the Hedgehog pathway, into two Phase 2 clinical studies for the treatment of idiopathic pulmonary fibrosis (IPF) in 2021.

                            Brand Name : ENV-101

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            January 07, 2021

                            Lead Product(s) : Taladegib

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Highest Development Status : Phase I

                            Sponsor : Omega Funds

                            Deal Size : $62.0 million

                            Deal Type : Series A Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth